Biodrug Delivery Systems: Do mRNA Lipid Nanoparticles Come of Age?

8Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

Abstract

As an appealing alternative to treat and prevent diseases ranging from cancer to COVID-19, mRNA has demonstrated significant clinical effects. Nanotechnology facilitates the successful implementation of the systemic delivery of mRNA for safe human consumption. In this manuscript, we provide an overview of current mRNA therapeutic applications and discuss key biological barriers to delivery and recent advances in the development of nonviral systems. The relevant challenges that LNPs face in achieving cost-effective and widespread clinical implementation when delivering mRNA are likewise discussed.

Cite

CITATION STYLE

APA

Puccetti, M., Schoubben, A., Giovagnoli, S., & Ricci, M. (2023, February 1). Biodrug Delivery Systems: Do mRNA Lipid Nanoparticles Come of Age? International Journal of Molecular Sciences. MDPI. https://doi.org/10.3390/ijms24032218

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free